Clinical trial
A Phase IIa ,Randomized, Double-blind, Placebo-controlled, Dose-exploration Study of JMKX000189 in Treatment of Moderate to Severe Active Systemic Lupus Erythematosus
NCT05967520 is registered in ClinicalTrials.gov with Jemincare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa ,Randomized, Double-blind, Placebo-controlled, Dose-exploration Study of JMKX000189 in Treatment of Moderate to Severe Active Systemic Lupus Erythematosus
- Lead sponsor
- Jemincare
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 21, 2023
- Completion date
- December 31, 2025
- Enrollment
- 48 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.